Biostime swallows Aussie vitamin maker for $992m

The Chinese baby formula maker's deal for Australia's Swisse Wellness shows SOEs have rivals for overseas M&A targets. But some wonder if Biostime is fighting above its weight.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES